Cancer Immunotherapies
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
122
NCT04041310
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 21, 2019
Completion: Oct 30, 2026
NCT04990479
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
Phase: Phase 1
Start: Jun 11, 2021
Completion: Mar 5, 2024
Loading map...